All In Biotech

Drug Trial Radar · NCT03334435

A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis

A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Adult Patients With Atopic Dermatitis

Last checked: Nov 20, 2026Latest source record: Sep 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,645 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,645

Actual

Start

Mar 28, 2018

Primary completion

Sep 21, 2020

Study completion Jul 12, 2023

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
Collaborators
Incyte Corporation
First posted
Nov 7, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the long-term safety and efficacy of baricitinib in participants with atopic dermatitis. Participants were enrolled in this study from the originating studies (JAHL, JAHM, JAIY) or were directly enrolled in the open-label arm.

Conditions

  • Atopic Dermatitis

Interventions

  • BaricitinibDrug

    Administered orally

  • PlaceboDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Responder and Partial Responders (RPR): Percentage of Participants From Monotherapy Studies (JAHL, JAHM) Who Achieved a Response of Investigator's Global Assessment (IGA) 0 or 1Time frame: Weeks 16, 36 and 52
  2. RPR: Percentage of Participants From Combination Therapy Study (JAIY) Who Achieved a Response of IGA 0 or 1Time frame: Weeks 16, 36, and 52

Locations

185 sites in 19 countries. Site status is shown where the registry gives one.

  • Centro de Investigaciones Metabólicas (CINME)

    Buenos Aires, Argentina

  • Buenos Aires Skin

    Ciudad Autonoma Buenos Aires, Argentina

  • Fundacion CIDEA

    Ciudad Autonoma Buenos Aires, Argentina

  • Instituto de Neumonología y Dermatología

    Ciudad Autonoma Buenos Aires, Argentina

  • Psoriahue Medicina Interdisciplinaria

    Ciudad Autonoma Buenos Aires, Argentina

  • Parra Dermatología

    Mendoza, Argentina

  • CEDIC-Centro de Investigaciones Clinicas

    Caba, Buenos Aires, Argentina

  • Woden Dermatology

    Phillip, Australian Capital Territory, Australia

  • Skin & Cancer Foundation Australia

    Westmead, New South Wales, Australia

  • The Skin Centre

    Benowa, Queensland, Australia

  • Veracity Clinical Research Pty Ltd

    Woolloongabba, Queensland, Australia

  • Clinical Trials SA Pty Ltd

    Adelaide, South Australia, Australia

  • Skin and Cancer Foundation Inc.

    Carlton, Victoria, Australia

  • Fremantle Dermatology

    Perth, Western Australia, Australia

  • KA Rudolfstiftung

    Vienna, Austria

  • AKH

    Vienna, Austria

  • KH Hietzing mit neurologischem Zentrum Rosenhügel

    Vienna, Austria

  • Sozialmed. Zentrum Ost - Donauspital

    Vienna, Austria

  • Universitätsklinikum Graz

    Graz, Styria, Austria

  • Ordensklinikum Linz GmbH - Elisabethinen

    Linz, Upper Austria, Austria

  • Kozni ambulance Kutna Hora, s.r.o.

    Kutná Hora, Central Bohemia, Czechia

  • Clintrial, s.r.o.

    Prague, Hl. M. Praha, Czechia

  • Fakultni nemocnice Kralovske Vinohrady

    Prague, Hl. M. Praha, Czechia

  • Fakultni Nemocnice v Motole

    Prague, Hl. M. Praha, Czechia

  • Nemocnice Na Bulovce

    Prague, Hl. M. Praha, Czechia

  • Nemocnice Novy Jicin a.s.

    Nový Jičín, Moravian-Silesian Region, Czechia

  • Fakultni Nemocnice Plzen

    Plzen-Bory, Plzeň Region, Czechia

  • Fakultni Nemocnice U svate Anny

    Brno, South Moravian, Czechia

  • Krajska zdravotni a.s. - Masarykova nemocnice v Usti nad Labem, o.z.

    Ústí nad Labem, Ustecký Kraj, Czechia

  • Gentofte Hospital

    Hellerup, Capital Region, Denmark

  • Aarhus Universitehospital Marselisborg Centret

    Aarhus, Region Midtjyland, Denmark

  • CHU de Bordeaux Hopital Saint Andre

    Bordeaux, France

  • CHU Grenoble Alpes

    Grenoble Cédex 9, France

  • Chru De Nantes Hotel-Dieu

    Nantes, France

  • CHU de Nice Hopital de L'Archet

    Nice, France

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, France

  • Hopital Larrey

    Toulouse, France

  • Hopital Saint-Louis

    Paris, Cedex 10, France

  • Universitätsklinikum Aachen AöR - Klinik für Dermatologie und Allergologie - Hautklinik

    Aachen, Germany

  • Charité Universitätsmedizin Berlin

    Berlin, Germany

Showing 40 of 185 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.